Literature DB >> 18829567

Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition.

Ilenia Pellicciotta1, Xochitl Cortez-Gonzalez, Roman Sasik, Yoram Reiter, Gary Hardiman, Pierre Langlade-Demoyen, Maurizio Zanetti.   

Abstract

Histone deacetylases (HDAC) modify the architecture of chromatin, leading to decreased gene expression, an effect that is reversed by HDAC inhibition. The balance between deacetylation and acetylation is central to many biological events including the regulation of cell proliferation and cancer but also the differentiation of immune T cells. The effects of HDAC inhibition on the interaction between antitumor effector T cells and tumor cells are not known. Here, we studied presentation of a universal self-tumor antigen, telomerase reverse transcriptase, in human tumor cells during HDAC inhibition. We found that HDAC inhibition with trichostatin A was associated with a decreased presentation and diminished killing of tumor cells by CTLs. Using gene array analysis, we found that HDAC inhibition resulted in a decrease of genes coding for proteasome catalytic proteins and for tapasin, an endoplasmic reticulum resident protein involved in the MHC class I pathway of endogenous antigen presentation. Our findings indicate that epigenetic changes in tumor cells decrease self-tumor antigen presentation and contribute to reduced recognition and killing of tumor cells by cytotoxic T lymphocytes. This mechanism could contribute to tumor escape from immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829567     DOI: 10.1158/0008-5472.CAN-08-1014

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity.

Authors:  Xiaodan Qin; William D Denton; Leah N Huiting; Kaylee S Smith; Hui Feng
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-07-07       Impact factor: 8.250

Review 2.  A second chance for telomerase reverse transcriptase in anticancer immunotherapy.

Authors:  Maurizio Zanetti
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

Review 3.  The evolving paradigm of cell-nonautonomous UPR-based regulation of immunity by cancer cells.

Authors:  M Zanetti; J J Rodvold; N R Mahadevan
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

Review 4.  Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.

Authors:  Karrune V Woan; Eva Sahakian; Eduardo M Sotomayor; Edward Seto; Alejandro Villagra
Journal:  Immunol Cell Biol       Date:  2011-11-22       Impact factor: 5.126

5.  Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8⁺ T cell priming.

Authors:  Navin R Mahadevan; Veronika Anufreichik; Jeffrey J Rodvold; Kevin T Chiu; Homero Sepulveda; Maurizio Zanetti
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

6.  Regulation of immune responses by histone deacetylase inhibitors.

Authors:  Paul V Licciardi; Tom C Karagiannis
Journal:  ISRN Hematol       Date:  2012-03-18

7.  Nuclear translocation of telomerase reverse transcriptase is a critical process in lymphatic metastasis of nasopharyngeal carcinoma.

Authors:  Ting-Ting Wu; Chen Chen; Shi-Ming Chen; Yong Xu; Yan Wang; Zhe Chen; Fei Wang; Bo-Kui Xiao; Ze-Zhang Tao
Journal:  Oncol Lett       Date:  2014-11-07       Impact factor: 2.967

8.  Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.

Authors:  Sofia R Gameiro; Anthony S Malamas; Kwong Y Tsang; Soldano Ferrone; James W Hodge
Journal:  Oncotarget       Date:  2016-02-16

9.  Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function.

Authors:  Matthew Pace; James Williams; Ayako Kurioka; Andrew B Gerry; Bent Jakobsen; Paul Klenerman; Nneka Nwokolo; Julie Fox; Sarah Fidler; John Frater
Journal:  PLoS Pathog       Date:  2016-08-16       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.